



Proteins Interacting with PCSK9: A Potential for Personalized Medicine

Lopez D*

Department of Pharmaceutical Sciences, North Carolina Central University, Durham, NC 27707, USA

Short Communication

Hypercholesterolemia is still a major issue in the United States with 73.5 million adults suffering from this illness (<https://www.cdc.gov/cholesterol/facts.htm>; accessed: May 9, 2017). The proprotein convertase subtilisin/kexin 9 (PCSK9) is one of the genes identified as causative of familial hypercholesterolemia (FH) in an autosomal dominant manner [1-3]. Serum levels of PCSK9 are associated positively with LDL concentration in FH patients and appear to contribute to the phenotypic severity of the FH disorder [4].

This disease improves with a proper diet, an exercise program, and in many cases, with the use of cholesterol-lowering treatments, such as statins [5,6]. Unfortunately, many hypercholesterolemic patients are unable to achieve the recommended target levels of low density lipoprotein (LDL)-cholesterol usually due to resistance to statin [7,8]. Interestingly, PCSK9 has been identified as one of the genes responsible for statin resistance [9]. Other patients (10-25%) suffer from statin intolerance limiting the use of these drugs in these patients [7,8]. Other side effects of statins that concern many physicians and patients are diabetes [10,11], reduced mental performance [12], cataracts development [13]. However, these effects usually happen in a small number of patients.

Both gain-of-function (GOF) and loss-of-function (LOF) mutations in the PCSK9 gene have been identified. The GOF mutations of PCSK9 lead to hypercholesterolemia and a higher risk of atherosclerotic-related diseases [3,14-16]. The LOF mutations, on the other hand, are associated with hypocholesterolemia and a significant protection against cardiovascular diseases [17-20]. Many LOF mutations are more prevalent in African-Americans than in other ethnic populations [18,19].

OPEN ACCESS

*Correspondence:

Dayami Lopez, Department of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise (BRITE), College of Arts and Sciences, North Carolina Central University, Durham, NC 27707, USA, Tel: 919-530-6914; Fax: 919-530-6600;

E-mail: lopezd@nccu.edu

Received Date: 10 May 2017

Accepted Date: 12 May 2017

Published Date: 19 May 2017

Citation:

Lopez D. Proteins Interacting with PCSK9: A Potential for Personalized Medicine. *Remed Open Access*. 2017; 2: 1056.

Copyright © 2017 Lopez D. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Although secreted by many tissues, the majority of the PCSK9 present in the serum come from the liver, small intestines, and kidneys [21]. PCSK9 is also found in cerebrospinal fluid and atherosclerotic plaques (CSF) [22,23]. Plasma PCSK9 levels in humans range from 30 ng/mL up to 4 µg/mL [24,25]. The levels of wild-type PCSK9 are positively correlated with the levels of atherogenic lipoproteins such as large very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), the smallest LDL, the smallest high density lipoprotein (HDL), and all remnant lipoproteins in a patient specific manner [25,26].

PCSK9 controls serum LDL levels by influencing the expression of the LDL receptor at the plasma membrane, especially in hepatic cells [27-29]. PCSK9 also stimulates degradation of the VLDL receptor, the apolipoprotein (Apo) E receptors 1 and 2 (ApoER and ApoER2), the cluster of differentiation 36 and 81, beta-secretase 1, and the epithelial (NA+) channel [30-33]. Based on the extent of PCSK9's targets, it is expected that this convertase controls multiple pathways. In fact, high PCSK9 levels appear to lead to, or the consequence of, the accumulation of ApoB-containing lipoproteins in the circulation, including lipoprotein (a) [34-36], obesity [25,37,38] diabetes [38-40], inflammation [41-43], atherosclerotic plaque development [44,45], thrombosis [46-49], hypertension [25,50], and apoptosis in different organs [51-54]. Upregulation of PCSK9 is seen during cerebral ischemia [55], myocardial infarction [48,56], kidney disease [57,58], and hepatic cancer [59]. Thus, watching plasma PCSK9 levels is recommended to determine disease severity in patients [60,61]. Having PCSK9 is also beneficial since this protein is involved in brain development, especially the cerebellum [62], liver regeneration [63,64], and preventing infections [65,66]. Therefore, the identification of protein partners of the PCSK9 function is critical to personalize treatment for hypercholesterolemic patients.

Thus far, several proteins have been identified that interact with PCSK9. Annexin A2 (AnxA2), for example, plays a fundamental role in fibrinolysis, regulation of the LDL receptor and cellular redox regulation [67]. AnxA2 regulates the LDL receptor by directly controlling the PCSK9-

dependent degradation of the receptor [68-70]. This protein works by directly binding to PCSK9, and this binding prevents the interaction of PCSK9 with the receptor [70]. AnxA2 also inhibits the translation of the PCSK9 mRNA resulting in a reduction in PCSK9 protein expression [68].

Matrix metalloproteinase-2 (MMP-2) is another protein shown to interact with PCSK9 [71]. MMP-2 works mainly by cleaving PCSK9 preventing the LDL receptor degradation [71]. Precursor protein-like protein-2 (APLP2) is another factor that interacts with PCSK9 and mediates the delivery of PCSK9 to lysosomes via a mechanism that does not require internalization of PCSK9 via the LDL receptor [72,73]. Interestingly, another study reported that APLP2 does not affect the PCSK9-mediated degradation of the LDL receptor despite its interaction with PCSK9 [74].

E3 ubiquitin ligase cellular inhibitor of apoptosis protein 1 (c-IAP1) binds PCSK9 and enhances the autocatalytic activity of PCSK9 [75]. Also, c-IAP1 promotes the ubiquitination of PCSK9 targeting this convertase to the lysosome [75]. Other proteins that interact with PCSK9 and modulate PCSK9's expression/function are Sar1B [76], amyloid precursor protein (APP) [72], sortilin [74], and GRP94 [77]. Sar1B reduces the expression of intestinal PCSK9 [76]. Sortilin is involved in secretion of PCSK9 [74]. GRP94 has been shown to inhibit the PCSK9-dependent degradation of the LDL receptor [77]. Other ways to reduce the levels of PCSK9 in plasma are by activating the deacetylases sirtuin 1/6 (Sirt1/6) [78,79] and by upregulating tribbles pseudokinase 1 (TRIB1) [80]. Although many proteins that interact with PCSK9 have been identified, none of these proteins is specific for one of the effects of PCSK9 described above.

The use of monoclonal antibody therapy to inhibit PCSK9 and treat hypercholesterolemia has some promise. This type of treatment can reduce serum LDL levels up to 81% [81-84]. The levels of total cholesterol, triglycerides, Apo B, and Apo (a) are also reduced with this treatment [81,83,85]. Unfortunately, neurocognitive events, which are a growing concern and new-onset diabetes, have been reported in patients receiving this type of treatment [81-83]. Other side-effects reported are gastrointestinal disturbances, infections, ophthalmologic events, and neutralizing antibodies [81-84].

In addition to the side effects, one major consideration when using PCSK9 inhibitors is how low LDL-cholesterol can go. There are concerns that very low levels of LDL-cholesterol may cause hemorrhagic stroke, cancer, hypertension, diabetes, reproductive problems, and neurocognitive dysfunction [86,87]. However, no association between low LDL-cholesterol levels and conditions such as hemorrhagic stroke or cancer has been found [88,89]. Related to the brain, statins, even if they cannot cross the blood-brain barrier, have the ability to alter the lipid composition of this organ [90]. Thus, there is a question of whether the inhibitors of PCSK9 can do the same. The association between low LDL-cholesterol and diabetes has been confirmed using clinical trials [91,92]. On the positive side, for the first time, there is a possibility of curing atherosclerosis [93].

At this point, it is critical if we know more about the different functions of PCSK9 and which proteins can modulate PCSK9's function. Patients on statins could develop drug resistance or intolerance, or they may just develop side effects that might be too unbearable to continue the treatment. PCSK9 inhibitors appear to be a solution, but their cost and possibility of developing that patients could develop more serious side effects than when

using statins have prevented broadening the utilization of these biologicals. More research is needed to identify additional regulators of PCSK9 function. These regulators could later become therapeutic targets that could be used to develop personalized treatment options for hypercholesterolemic patients considering the patient-specific metabolic state.

Acknowledgement

This publication was supported by funds from the State of North Carolina and the BRITE Institute.

References

- Gu HM, Zhang DW. Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9. *J Biomed Res.* 2015;29(5):356-61.
- Di Taranto, D'Agostino MN, Fortunato G. Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis. *Nutr Metab Cardiovasc Dis.* 2015;25(11):979-87.
- Alves AC, Etxebarria A, Medeiros AM, Benito-Vicente A, Thedrez A, Passard M, et al. Characterization of the first PCSK9 gain of function homozygote. *J Am Coll Cardiol.* 2015;66(19):2152-4.
- Huijgen R, Fouchier SW, Denoun M, Hutten BA, Vissers MN, Lambert G, et al. Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. *J Lipid Res.* 2012;53(5):979-83.
- Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA. Familial hypercholesterolemia: current treatment and advances in management. *Expert Rev Cardiovasc Ther.* 2008;6(4):567-81.
- Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolemia: a long term cohort study. *BMJ.* 2008;337:a2423.
- Pedersen TR. The Success Story of LDL Cholesterol Lowering. *Circ Res.* 2016;118(4):721-31.
- Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. *J Clin Lipidol.* 2014;8:S72-81.
- Reiner Z. Resistance and intolerance to statins. *Nutr Metab Cardiovasc Dis.* 2014;24(10):1057-66.
- Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N. The Diabetes Subpanel of the National Lipid Association Expert Panel. An assessment by the Statin Diabetes Safety Task Force: 2014 update. *J Clin Lipidol.* 2014;8(3 Suppl):S17-29.
- Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. *BMJ.* 2013;346:f2610.
- King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. *Pharmacotherapy.* 2003;23(12):1663-7.
- Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. *JAMA Ophthalmol.* 2013;131(11):1427-34.
- Abifadel M, Guerin M, Benjannet S, Rabès JP, Le Goff W, Julia Z, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. *Atherosclerosis.* 2012;223(2):394-400.
- Adi D, Xie X, Liu F, Yi-Tong M, Abudoukelimu M, Wu Y, et al. Relationships between genetic polymorphisms of E670G in PCSK9 gene and coronary artery disease: a meta-analysis. *Int J Clin Exp Med.* 2015;8(8):13251-58.

16. Drouin-Chartier JP, Tremblay AJ, Hogue JC, Ooi TC, Lamarche B, Couture P. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype. *Metabolism*. 2015;64(11):1541-7.
17. Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. *Arterioscler Thromb Vasc Biol*. 2006;26(5):1094-100.
18. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. *Atherosclerosis*. 2007;193(2):445-8.
19. Sirois F, Gbeha E, Sanni A, Chretien M, Labuda D, Mbikay M. Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population. *Genet Test*. 2008;12(3):377-80.
20. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. *Am J Hum Genet*. 2006;79(3):514-23.
21. Langhi C, Le May C, Gmyr V, Vandewalle B, Kerr-Conte J, Krempf M, et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. *Biochem Biophys Res Commun*. 2009;390(4):1288-93.
22. Chen YQ, Troutt JS, Konrad RJ. PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. *Lipids*. 2014;49:445-55.
23. Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. *Atherosclerosis*. 2012;220:381-86.
24. Dubuc G, Tremblay M, Paré G, Jacques H, Hamelin J, Benjannet S, et al. A new method for measurement of total plasma PCSK9: clinical applications. *J Lipid Res*. 2010;51(1):140-9.
25. Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. *Atherosclerosis*. 2010;213(2):632-6.
26. Lambert G, Petrides F, Chatelais M, Blom DJ, Choque B, Tabet F, et al. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. *J Am Coll Cardiol*. 2014;63:2365-73.
27. Cameron J, Holla RL, Ranheim T, Kulseth MA, Berge KE, Leren TP. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. *Hum Mol Genet*. 2006;15(9):1551-8.
28. Saavedra YG, Day R, Seidah NG. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. *J Biol Chem*. 2012;287(52):43492-501.
29. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med*. 2006;354(12):1264-72.
30. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. *J Biol Chem*. 2008;283(4):2363-72.
31. Demers A, Samami S, Lauzier B, Des Rosiers C, Ngo Sock ET, Ong H, et al. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver. *Arterioscler Thromb Vasc Biol*. 2015;35:2517-25.
32. Jonas MC, Costantini C, Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. *EMBO Rep*. 2008;9(9):916-22.
33. Le QT, Blanchet M, Seidah NG, Labonte P. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. *J Biol Chem*. 2015;290(38):23385-400.
34. Chan DC, Wong AT, Pang J, Barrett PH, Watts GF. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state. *Clin Sci (Lond)* 2015;128(6):379-85.
35. Wassef H, Bissonnette S, Saint-Pierre N, Lamantia V, Cyr Y, Chrétien M, et al. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans. *J Clin Lipidol*. 2015;9(5):664-75.
36. Tada H, Kawashiri MA, Yoshida T, Teramoto R, Nohara A, Konno T, et al. Lipoprotein (a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations. *Circ J*. 2016;80(2):512-8.
37. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. *Arterioscler Thromb Vasc Biol*. 2011;31(4):785-91.
38. Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. *Clin Chem*. 2009;55(9):1637-45.
39. Yang SH, Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, et al. Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes. *Diabetes Metab Res Rev*. 2016;32(2):193-9.
40. Saavedra YG, Dufour R, Baass A. Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk. *J Clin Lipidol*. 2015;9(6):786-93.
41. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C. Inflammation stimulates the expression of PCSK9. *Biochem Biophys Res Commun*. 2008;374(2):341-4.
42. Ding Z, Liu S, Wang X, Deng X, Fan Y, Sun C, et al. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. *Antioxid Redox Signal*. 2015;22(9):760-71.
43. Miyazawa H, Honda T, Miyauchi S, Domon H, Okui T, Nakajima T, et al. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration. *Clin Chim Acta*. 2012;413(1-2):154-9.
44. Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. *Circulation*. 2012;125(7):894-901.
45. Al-Mashhadi RH, Sorensen CB, Kragh PM, Christoffersen C, Mortensen MB, Tolbod LP, et al. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. *Sci Transl Med*. 2013;5(166):166ra161.
46. Li S, Zhu CG, Guo YL, Xu RX, Zhang Y, Sun J, et al. The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease. *J Atheroscler Thromb*. 2015;22(1):76-84.
47. Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. *Atherosclerosis*. 2014;234(2):441-5.
48. Zhang Y, Zhu CG, Xu RX, Li S, Guo YL, Sun J, et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. *J Clin Lipidol*. 2014;8(5):494-500.
49. Li JJ, Li S, Zhang Y, Rui-Xia X, Yuan-Lin G, Cheng-Gang Z, et al. Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery

- Disease: A Prospective Observational Cohort Study. *Medicine (Baltimore)*. 2015;94(52):e2426.
50. Tran NT, Aslibekyan S, Tiwari HK, Zhi D, Sung YJ, Hunt SC, et al. PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies. *Front Genet* 2015;6:136.
51. Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, Dewpura T, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. *FEBS Lett*. 2010;584(4):701-6.
52. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. *Cell Metab*. 2010;12(5):467-82.
53. Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS, Liu LS. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. *Mol Cell Biochem*. 2012;359(1-2):347-58.
54. Kysenius K, Muggalla P, Mätlik K, Arumäe U, Huttunen HJ. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. *Cell Mol Life Sci*. 2012;69(11):1903-16.
55. Rousselet E, Marcinkiewicz J, Kriz J, Zhou A, Hatten ME, Prat A, et al. PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. *J Lipid Res*. 2011;52(7):1383-91.
56. Gencer B, Montecucco F, Nanchen D, Carbone F, Klingenberg R, Vuilleumier N, et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. *Eur Heart J*. 2016;37(6):546-53.
57. Jin K, Park BS, Kim YW, Vaziri ND. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. *Am J Kidney Dis*. 2014;63(4):584-89.
58. Sucajtyś-Szulc E, Szolkiewicz M, Swierczynski J, Rutkowski B. Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure. *Mol Cell Biochem*. 2016;411:281-87.
59. Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, et al. Decreased PCSK9 expression in human hepatocellular carcinoma. *BMC Gastroenterol*. 2015;15:176.
60. Le Bras M, Roquilly A, Deckert V, Langhi C, Feuillet F, Sébille V, et al. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. *J Clin Endocrinol Metab*. 2013;98(4):E732-6.
61. Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, Wu NQ, et al. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. *Ann Med*. 2015;47(5):386-93.
62. Poirier S, Prat A, Marcinkiewicz E, Paquin J, Chitramuthu BP, Baranowski D, et al. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. *J Neurochem*. 2006;98(3):838-50.
63. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. *Proc Natl Acad Sci U S A*. 2003;100(3):928-33.
64. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. *Hepatology*. 2008;48(2):646-54.
65. Labonté P, Begley S, Guévin C, Asselin MC, Nassoury N, Mayer G, et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. *Hepatology*. 2009;50(1):17-24.
66. Marlovits TC, Abrahamsberg C, Blaas D. Very-low-density lipoprotein receptor fragment shed from HeLa cells inhibits human rhinovirus infection. *J Virol*. 1998;72(12):10246-50.
67. Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. *Int J Mol Sci*. 2013;14(3):6259-305.
68. Ly K, Saavedra YG, Canuel M, Routhier S, Desjardins R, Hamelin J, et al. Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9. *J Biol Chem*. 2014;289(25):17732-46.
69. Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C, et al. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. *PLoS One*. 2012;7(7):e41865.
70. Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. *J Biol Chem*. 2008;283(46):31791-801.
71. Wang X, Berry E, Hernandez-Anzaldo S, Sun D, Adijiang A, Li L, et al. MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells. *FEBS Lett*. 2015;589(4):490-6.
72. DeVay RM, Shelton DL, Liang H. Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). *J Biol Chem*. 2013;288(15):10805-818.
73. DeVay RM, Yamamoto L, Shelton DL, Liang H. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function. *PLoS one*. 2015;10(4):e0125127.
74. Butkinaree C, Canuel M, Essalmani R, Poirier S, Benjannet S, Asselin MC, et al. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. *J Biol Chem*. 2015;290(30):18609-620.
75. Xu W, Liu L, Hornby D. c-IAP1 binds and processes PCSK9 protein: linking the c-IAP1 in a TNF- α pathway to PCSK9-mediated LDLR degradation pathway. *Molecules*. 2012;17(10):12086-101.
76. Sané A, Seidman E, Spahis S, Lamantia V, Garofalo C, Montoudis A, et al. New Insights In Intestinal Sar1B GTPase Regulation and Role in Cholesterol Homeostasis. *J Cell Biochem*. 2015;116(10):2270-82.
77. Poirier S, Mamarbachi M, Chen WT, Lee AS, Mayer G. GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation. *Cell Rep*. 2015;13:2064-71.
78. Miranda MX, van Tits LJ, Lohmann C, Arsiwala T, Winnik S, Tailleux A, et al. The Sirt1 activator SRT3025 provides atheroprotection in ApoE^{-/-} mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. *Eur Heart J*. 2015;36(1):51-9.
79. Tao R, Xiong X, DePinho RA, Deng CX, Dong XC. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. *J Biol Chem*. 2013;288(41):29252-9.
80. Nagiec MM, Skepner AP, Negri J, Eichhorn M, Kuperwasser N, Comer E, et al. Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression. *PLoS one*. 2015;10(3):e0120295.
81. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. *BMC Med*. 2015;13:123.
82. Devito F, Zito A, Ricci G, Carbonara R, Dentamaro I, Cortese F, et al. Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia. *Pharmacol Res*. 2015;102:168-75.
83. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. *Eur Heart J*. 2015;36(43):2996-3003.
84. Reiner L. PCSK9 inhibitors--past, present and future. *Expert Opin Drug Metab Toxicol*. 2015;11(10):1517-21.

85. Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. *J Am Heart Assoc.* 2015;4(6):e001937.
86. LaRosa JC, Pedersen TR, Somaratne R, Wasserman SM. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. *Am J Cardiol.* 2013;111(8):1221-9.
87. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA.* 2011;305(24):2556-64.
88. Cholesterol Treatment Trialists, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010;376(9753):1670-81.
89. Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS One.* 2012;7(1):e29849.
90. Vecka M, Tvrzická E, Stanková B, Novák F, Nováková O, Zák A. Hypolipidemic drugs can change the composition of rat brain lipids. *Tohoku J Exp Med.* 2004;204(4):299-308.
91. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet.* 2010;375(9716):735-42.
92. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet.* 2012;380:565-71.
93. Robinson JG, Gidding SS. Curing atherosclerosis should be the next major cardiovascular prevention goal. *J Am Coll Cardiol.* 2014;63(25 Pt A):2779-85.